Clinical Trial Update: A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

View source ↗

Summary

This clinical trial update notes that the study of trastuzumab-MCC-DM1 in HER2-positive locally advanced or metastatic breast cancer is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab-MCC-DM1 (ado-trastuzumab emtansine)

Snippet

Sponsor: Genentech, Inc. | Conditions: Metastatic Breast Cancer | Status: NO_LONGER_AVAILABLE